Home » Stocks » FOLD

Amicus Therapeutics, Inc. (FOLD)

Stock Price: $9.27 USD -0.14 (-1.44%)
Updated Aug 3, 2021 11:56 AM EDT - Market open
Market Cap 2.50B
Revenue (ttm) 266.76M
Net Income (ttm) -253.57M
Shares Out 264.37M
EPS (ttm) -0.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day August 3
Last Price $9.27
Previous Close $9.40
Change ($) -0.14
Change (%) -1.44%
Day's Open 9.39
Day's Range 9.09 - 9.42
Day's Volume 329,634
52-Week Range 8.60 - 25.39

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The European Commission has approved Amicus Therapeutics Inc (NASDAQ: FOLD) Galafold (migalastat) for use in adolescents with Fabry disease who have an amenable mutation.  Galafold is already approved i...

1 day ago - Benzinga

Galafold® is the First and Only Oral Therapy Approved in the EU for the Long-term Treatment of Adolescents with Fabry Disease Aged 12 years and older with an Amenable Mutation Galafold® is the First and...

1 day ago - GlobeNewsWire

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 days ago - Zacks Investment Research

PHILADELPHIA, July 27, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 5, 2021 at 8:30...

1 week ago - GlobeNewsWire

PHILADELPHIA, June 14, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an est...

1 month ago - GlobeNewsWire

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Permits All Eligible Individuals with Late-Onset Pompe Disease Access to AT-GAA Prior to Marketing Authorization in the UK

1 month ago - GlobeNewsWire

PHILADELPHIA, May 28, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Goldman Sac...

2 months ago - GlobeNewsWire

With the trading day more than halfway over, the markets were somewhat mixed going into the weekend.

Other stocks mentioned: BLMN, STX, APLS, ONEM, PLCE, SBRA
2 months ago - 24/7 Wall Street

PHILADELPHIA, May 21, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the 16th Interna...

2 months ago - GlobeNewsWire

Amicus (FOLD) reports a wider Q1 loss and sales miss estimates.

2 months ago - Zacks Investment Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -8.70% and -7.47%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Amicus Therapeutics (NASDAQ:FOLD) rose 0.6% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 28.57% over the past year to ($0.25), whic...

2 months ago - Benzinga

Galafold ® (migalastat) Performance Reflects Continued Strong Adoption in All Key Global Regions; On-Track to Achieve Revenue Guidance of $300M-$315M

2 months ago - GlobeNewsWire

PHILADELPHIA, May 07, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the foll...

2 months ago - GlobeNewsWire

Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme

2 months ago - GlobeNewsWire

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Amicus Therapeutics Inc (NASDAQ: FOLD) has completed a Type B Pre-Biologics License Application (BLA) meeting with the FDA for AT-GAA (cipaglucosidase alfa co-administered with miglustat) for Pompe dise...

3 months ago - Benzinga

Great Place to Work® Certification in the United Kingdom, Spain, Italy and Germany Great Place to Work® Certification in the United Kingdom, Spain, Italy and Germany

3 months ago - GlobeNewsWire

PHILADELPHIA, April 26, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, May 10, 2021 at 8:30 a....

3 months ago - GlobeNewsWire

Investors cheered an analyst's upgrade of the biotech stock.

3 months ago - The Motley Fool

Amicus (FOLD) reports a wider-than-expected Q4 loss but sales beat estimates.

5 months ago - Zacks Investment Research

With the trading day more than halfway over, the broad markets pulled back from their impressive start to the week.

Other stocks mentioned: CCL, RCL, BMO, DRNA, GLNG, SWCH, TRUE
5 months ago - 24/7 Wall Street

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -12.50% and 0.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of Amicus Therapeutics (NASDAQ:FOLD) moved higher by 0.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 22.86% over the past year to ($0.2...

5 months ago - Benzinga

Amicus Therapeutics (NASDAQ:FOLD) unveils its next round of earnings this Monday, March 01. Get prepared with Benzinga's ultimate preview for Amicus Therapeutics's Q4 earnings.

5 months ago - Benzinga

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Amicus Therapeutics said Thursday its rare-disease treatment failed to outperform a standard drug on one key measure in a Phase 3 test. In response, FOLD stock plunged on Friday.

5 months ago - Investors Business Daily

Amicus Therapeutics said Thursday its rare-disease treatment failed to outperform a standard drug on one key measure in a Phase 3 test. In response, FOLD stock plunged on Friday.

5 months ago - Investors Business Daily

John Crowley, Amicus Therapeutics, discusses drug trial results for Pompe disease

YouTube video

CNBC Meg Tirrell talks with Amicus Therapeutics CEO John Crowley about trial results for a drug to treat Pompe disease. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Karen ...

5 months ago - CNBC Television

Amicus releases phase 3 results in Pompe disease trial

YouTube video

CNBC's senior health and science reporter Meg Tirrell reports Amicus showed results in its phase 3 trial to address Pompe disease. The drug showed it can help people walk and significantly slowed the ra...

5 months ago - CNBC Television

Rolling BLA submission for AT-GAA planned for completion in Q2 and other global regulatory submissions for approval expected throughout 2021

5 months ago - GlobeNewsWire

Initial Data Suggest Early Signs of Disease Stabilization in Children with Fatal Neurologic Disease

5 months ago - GlobeNewsWire

Amicus Optimized Transgene Show Greater Substrate Reduction than Wild Type Construct Across All Tissues and Doses

5 months ago - GlobeNewsWire

Investors need to pay close attention to Amicus Therapeutics (FOLD) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

CRANBURY, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines f...

6 months ago - GlobeNewsWire

CRANBURY, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the 39th Annual J.P. Morg...

6 months ago - GlobeNewsWire

The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.

Other stocks mentioned: EDIT, FATE, RARE, XLRN
7 months ago - Zacks Investment Research

Biopharma stocks are risky investment bets that sway wildly in reaction to catalytic events. Binary events scheduled for Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Sarepta Therapeutics Inc (NASDAQ: SR...

Other stocks mentioned: SRPT
7 months ago - Benzinga

Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

CRANBURY, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines f...

7 months ago - GlobeNewsWire

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?

7 months ago - Zacks Investment Research

Amicus (FOLD) initiates a rolling biologics license application (BLA) submission to the FDA for AT-GAA, for the treatment of late onset Pompe disease.

8 months ago - Zacks Investment Research

On Track for Completing the BLA Submission in 1H2021

8 months ago - GlobeNewsWire

The shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)  are up 1.3% at $22.69 at last check, after hitting a Nov. 18, all-time-high of $23.19.

8 months ago - Schaeffers Research

CRANBURY, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Evercore...

8 months ago - GlobeNewsWire

Amicus (FOLD) reports a wider-than-expected loss but sales beat estimates in the third quarter of 2020.

8 months ago - Zacks Investment Research

Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -10.00% and 3.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

CRANBURY, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the Credit Suisse 29th An...

9 months ago - GlobeNewsWire

About FOLD

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and ... [Read more...]

Industry
Biotechnology
IPO Date
May 31, 2007
CEO
John Crowley
Employees
483
Stock Exchange
NASDAQ
Ticker Symbol
FOLD
Full Company Profile

Financial Performance

In 2020, FOLD's revenue was $260.89 million, an increase of 43.16% compared to the previous year's $182.24 million. Losses were -$276.85 million, -22.32% less than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for FOLD stock is "Buy." The 12-month stock price forecast is 16.50, which is an increase of 78.09% from the latest price.

Price Target
$16.50
(78.09% upside)
Analyst Consensus: Buy